Intuitive Surgical (ISRG) Set to Release Earnings on Tuesday

Intuitive Surgical (NASDAQ:ISRG) is anticipated to release its Q3 2026 results after the market closes on Tuesday, October 20th. Analysts expect the company to post earnings of $2.65 per share and revenue of $2.91 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, October 20, 2026 at 4:30 PM ET.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, analysts expect Intuitive Surgical to post $8.87 EPS for the current fiscal year and $10.02 EPS for the next fiscal year.

Intuitive Surgical Price Performance

ISRG stock opened at $426.70 on Monday. Intuitive Surgical has a twelve month low of $328.57 and a twelve month high of $603.88. The firm has a market cap of $150.74 billion, a PE ratio of 48.88, a price-to-earnings-growth ratio of 3.22 and a beta of 1.46. The business has a 50 day moving average of $391.43 and a 200 day moving average of $409.44.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts at Erste Group Bank raised their earnings estimates for ISRG, suggesting improved expectations for the company’s upcoming results and longer-term profitability. Erste Group Bank Analysts Boost Earnings Estimates for ISRG
• Positive Sentiment: Recent results have shown double-digit growth in robotic-surgery procedures, revenue and Intuitive Surgical’s installed base of systems. That underlying operating momentum remains a key support for the investment case despite the stock’s broader underperformance this year. Intuitive Surgical Valuation and Growth
• Positive Sentiment: The shares increased in the prior session and outperformed the broader market that day, reflecting some investor support ahead of the earnings release. ISRG Beats Stock Market Upswing
• Neutral Sentiment: Investors are focused on third-quarter procedure growth, da Vinci system demand, revenue, margins and other operating metrics—not just earnings per share and revenue—to determine whether recent momentum is sustainable. ISRG Ahead of Q3 Earnings
• Negative Sentiment: Expectations are tempered by slowing U.S. procedure growth and headwinds in China. These issues could pressure system placements and margins, increasing the risk of an earnings-related market reaction. ISRG Q3 Earnings Preview
• Negative Sentiment: Despite double-digit growth, shares have declined substantially during 2026 and trade at a premium valuation. Investors are questioning whether a valuation around 33 times expected earnings adequately reflects the company’s growth prospects, particularly if procedure growth slows. ISRG Valuation Analysis

Insider Activity at Intuitive Surgical

In related news, Director Amy Ladd sold 72 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total value of $28,303.20. Following the completion of the transaction, the director directly owned 179 shares in the company, valued at $70,364.90. The trade was a 28.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the transaction, the executive vice president directly owned 5,320 shares in the company, valued at $2,016,280. This trade represents a 6.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 12,370 shares of company stock valued at $4,891,989 over the last ninety days. Corporate insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Intuitive Surgical in a research note on Friday, August 14th. Sanford C. Bernstein restated an “outperform” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. UBS Group restated a “buy” rating on shares of Intuitive Surgical in a report on Tuesday, October 13th. BNP Paribas Exane raised Intuitive Surgical to an “outperform” rating in a research report on Tuesday, July 28th. Finally, Citigroup dropped their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $498.83.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.